Healthcare & Life Sciences
Selecta Biosciences
series-c-plus
series-c-plus
Stage
1
Investors
About
Selecta Biosciences is a clinical-stage biopharmaceutical company developing tolerogenic Synthetic Vaccine Particles (SVP™) intended to mitigate unwanted immune responses and enable non-immunogenic biologic therapies for rare and serious diseases.
Explore Selecta Biosciences's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.